Age-related changes in the upper respiratory microbiome are associated with SARS-CoV-2 susceptibility and illness severity

Jillian H. Hurst, PhD^{1,2}, Alexander W. McCumber, MS³, Jhoanna N. Aquino, BS¹, Javier Rodriguez, AS⁴, Sarah M. Heston, MD¹, Debra J. Lugo, MD¹, Alexandre T. Rotta, MD⁵, Nicholas A. Turner, MD, MHSc⁶, Trevor S. Pfeiffer, BS¹, Thaddeus C. Gurley, MS⁷, M. Anthony Moody, MD^{1,7}, Thomas N. Denny, MSc, MPhil⁷, John F. Rawls, PhD^{8,9}, Christopher W. Woods, MD, MPH^{6,7}, Matthew S. Kelly, MD, MPH^{1,9}

¹Department of Pediatrics, Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA; ²Children's Health and Discovery Institute, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA; ³Civil and Environmental Engineering Department, Duke University, Durham, North Carolina, USA; ⁴Children's Clinical Research Unit, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA; ⁵Department of Pediatrics, Division of Pediatric Critical Care Medicine, Duke University School of Medicine, Durham, North Carolina, USA; ⁶Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA; ⁷Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA; ⁸Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, USA; ⁹Duke Microbiome Center, Duke University School of Medicine, Durham, North Carolina, USA

Summary: Evaluation of nasopharyngeal microbiome profiles in children, adolescents, and young adults with a SARS-CoV-2-infected close contact identified specific bacterial species that vary in abundance with age and are associated with SARS-CoV-2 susceptibility and the presence of SARS-CoV-2-associated respiratory symptoms.

1 **Keywords:** COVID-19; community; pediatric; children; nasopharyngeal microbiome; *Corynebacterium*;
2 *Dolosigranulum*
3
4 **Corresponding Author:**
5 Matthew S. Kelly, MD, MPH
6 2301 Erwin Road
7 Durham, NC 27710
8 Phone: (919) 684-6335
9 Email: matthew.kelly@duke.edu

ABSTRACT

Children are less susceptible to SARS-CoV-2 and typically have milder illness courses than adults. We studied the nasopharyngeal microbiomes of 274 children, adolescents, and young adults with SARS-CoV-2 exposure using 16S rRNA gene sequencing. We find that higher abundances of *Corynebacterium* species are associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory symptoms, while higher abundances of *Dolosigranulum pigrum* are present in SARS-CoV-2-infected individuals without respiratory symptoms. We also demonstrate that the abundances of these bacteria are strongly, and independently, associated with age, suggesting that the nasopharyngeal microbiome may be a potentially modifiable mechanism by which age influences SARS-CoV-2 susceptibility and severity.

SARS-CoV-2, the etiological agent of coronavirus disease 2019 (COVID-19), has resulted in more than 100 million infections and two million deaths globally [1]. In contrast to most other respiratory viruses [2-4], children appear to be less susceptible to SARS-CoV-2 infection, and SARS-CoV-2-infected children typically have milder illness courses than adults. In a recent meta-analysis that included 32 studies of 41,640 children and adolescents less than 20 years of age and 268,945 adults 20 years of age or older, children and adolescents were estimated to have a 46% lower susceptibility to SARS-CoV-2 infection than adults [5]. Further, a higher incidence of SARS-CoV-2 infection has been observed with increasing age, even among infants, children, and adolescents [6]. Reporting data from a community-based study of SARS-CoV-2 infections, we previously demonstrated that at least one-third of SARS-CoV-2-infected children and adolescents are asymptomatic [7], and children who do develop symptomatic SARS-CoV-2 infection typically report mild respiratory symptoms [7-10]. Additionally, COVID-19 hospitalization rates and mortality among children are substantially lower than among adults of all ages, with only 576 hospitalizations and 208 deaths among children and adolescents less than 18 years of age reported during the first six months of the pandemic in the United States [11]. These data suggest that host biological or immunological factors that vary with age modify susceptibility to and severity of SARS-CoV-2 infection, and that an understanding of these host factors could inform development of novel strategies to prevent or treat SARS-CoV-2 infections in children and adults.

Given that the upper respiratory microbiome undergoes substantial shifts in early childhood [12-14], and is increasingly recognized to play a key role in the pathogenesis of respiratory virus infections [15-21], we hypothesized that changes in the upper respiratory microbiome with age might contribute to the differences in susceptibility to SARS-CoV-2 infection and the severity of SARS-CoV-2-associated respiratory symptoms among children and adults. In this study, we used 16S ribosomal RNA (rRNA) gene amplicon sequencing to characterize the nasopharyngeal microbiomes of 274 children, adolescents, and young adults with close contact with a SARS-CoV-2-infected individual. We describe associations

between the composition of the nasopharyngeal microbiome and SARS-CoV-2 infection. In addition, we identify bacterial species that are associated with the presence of respiratory symptoms among children with SARS-CoV-2 infection. Finally, we demonstrate that the relative abundances of these bacterial species within the nasopharyngeal microbiome are strongly, and independently, associated with age. Taken together, our findings demonstrate that age-associated changes in the upper respiratory microbiome may contribute to the varied susceptibility to and severity of SARS-CoV-2 infection among children and adults.

METHODS

Study Population

The Duke Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) study is a prospective cohort study of children, adolescents, and young adults with confirmed SARS-CoV-2 infection or close contact with an individual with confirmed SARS-CoV-2 infection [7]. This study is being conducted within the Duke University Health System in Raleigh-Durham, North Carolina. Eligible participants are less than 21 years of age and have close contact with an individual with SARS-CoV-2 infection confirmed by real-time PCR. Close contact is defined as an unprotected exposure within 6 feet to a confirmed case between 2 days before and 7 days after symptom onset or confirmation of SARS-CoV-2 infection in asymptomatic contacts. Close contacts include, but are not limited to, parents, siblings, other caregivers, and partners.

Study Procedures

We collected exposure, sociodemographic, and clinical data at enrollment through review of electronic medical records and a directed questionnaire conducted by telephone. We recorded any symptoms reported within the 2 weeks preceding study enrollment. In addition, we conducted follow-up

questionnaires for all participants 7 days after study enrollment to document new symptoms and healthcare encounters. For participants with one or more symptoms 7 days after study enrollment, additional questionnaires were administered 14 and 28 days after enrollment, or until the participant reported complete symptom resolution. We recorded the results of SARS-CoV-2 testing performed for clinical care. In addition, we conducted a home visit as soon as possible after study enrollment to collect a nasopharyngeal swab and other biospecimens. Participants who declined a home visit received a kit for self-collection of a mid-turbinate nasal swab. Nasopharyngeal and nasal samples were collected with nylon flocked swabs (Copan Italia, Brescia, Italy) and placed into RNAProtect (Qiagen, Hilden, Germany) prior to storage at -80°C. All nasopharyngeal and nasal samples were tested for SARS-CoV-2 using a real-time quantitative PCR assay, as previously described [7]. We classified participants as SARS-CoV-2-infected if SARS-CoV-2 was identified in either a clinical or research PCR assay. We considered SARS-CoV-2-infected individuals as having respiratory symptoms if they reported cough, rhinorrhea, nasal congestion, shortness of breath, sore throat, or anosmia at any point between 14 days prior to enrollment through the end of the study follow-up period. Finally, we classified participants into one of three groups: 1) SARS-CoV-2-uninfected; 2) SARS-CoV-2-infected *without* respiratory symptoms; and 3) SARS-CoV-2-infected *with* respiratory symptoms. The analyses presented herein were limited to study participants with an available nasopharyngeal sample.

Processing of nasopharyngeal samples for 16S ribosomal RNA sequencing

The Duke Microbiome Core Facility extracted DNA from nasopharyngeal samples using Powersoil Pro extraction kits (Qiagen) following the manufacturer's instructions. DNA concentrations were determined using Qubit dsDNA high-sensitivity assay kits (Thermo Fisher Scientific). Bacterial community composition was characterized by PCR amplification of the V4 variable region of the 16S rRNA gene using the forward primer 515 and the reverse primer 806 following the Earth Microbiome Project protocol [22]. These primers carry unique barcodes that allow for multiplexed sequencing. Equimolar 16S rRNA

PCR products from all samples were quantified and pooled prior to sequencing. Sequencing was performed by the Duke Sequencing and Genomic Technologies Core Facility on an Illumina MiSeq instrument configured for 250 base-pair paired-end sequencing. All samples were included in a single sample processing run with inclusion of both negative extraction and PCR controls. We analyzed raw sequences through a DADA2 pipeline [23] and assigned taxonomy to amplicon sequence variants (ASVs) using Silva SSU version 138 [24]. We identified and removed sequencing contaminants (n=40) using the *decontam* R package [25]. Samples with less than 1000 sequencing reads after quality filtering and contaminant removal were excluded. We obtained a median [interquartile range (IQR)] of 24,422 (17,799, 33,291) high-quality sequencing reads from the 274 samples included in these analyses. Sequencing reads were classified into 1,799 ASVs representing 316 bacterial genera from 20 phyla (**Supplemental Table 1**). We performed standard nucleotide REFSEQ BLAST searches of ASV reference sequences using the National Center for Biotechnology Information's Bacteria and Archaea 16S ribosomal RNA project database [26]. We assigned species information to ASVs using a best-hit approach based on the E value with a minimum percent identity of 99%.

Data Analysis

We first sought to characterize changes in nasopharyngeal microbiome diversity and composition that occur with age. We calculated nasopharyngeal microbiome alpha (Shannon and Chao1 indices) and beta diversity (Bray-Curtis dissimilarity) using the *phyloseq* R package [27]. We then fit linear regression models to evaluate associations between participant age and microbiome alpha diversity measures. The Chao1 index was not normally distributed and was thus log-transformed for these analyses. We then evaluated the association between age and nasopharyngeal microbiome composition with PERMANOVA using the *adonis* function within the *vegan* R package [28]. Finally, we used ANCOM-II [29] to fit linear models evaluating associations between age and the relative abundances of bacterial ASVs within the nasopharyngeal microbiome. An ASV was considered to be differentially abundant if it varied across the

independent variable of interest with respect to 80% of the other ASVs in the dataset (W statistic > 0.80). ASVs that were identified as structural zeros were not considered to be differentially abundant. All analyses of nasopharyngeal microbiome diversity and composition by age were adjusted for participant SARS-CoV-2 infection status and the presence of SARS-CoV-2-associated respiratory symptoms. We then used these same methods to evaluate associations between nasopharyngeal microbiome diversity and composition and SARS-CoV-2 infection status, adjusting for participant age. Finally, in analyses limited to SARS-CoV-2-infected individuals, we used these same methods to evaluate associations between the nasopharyngeal microbiome and the presence of respiratory symptoms among SARS-CoV-2-infected participants, adjusting for age. Our findings were not substantively changed when we additionally adjusted for sex and race in analyses of nasopharyngeal microbiome diversity and composition by age, SARS-CoV-2 status, or SARS-CoV-2-associated respiratory symptoms. Given that ANCOM-II produces only a list of differentially abundant ASVs, we used DESeq2 [30] to generate log₂-fold changes in abundance in order to determine the directionality of these associations. Analyses conducted in ANCOM-II and DESeq2 were limited to ASVs present in at least 5% of samples and adjusted for the false discovery rate using the Benjamini-Hochberg procedure. Analyses were performed using R version 4.0.3 [31] and all visualizations were created using the *ggplot2* R package [32].

RESULTS

Characteristics of the study population

Two hundred seventy-four children, adolescents, and young adults were included in these analyses (**Table 1**). Participants were classified as SARS-CoV-2-uninfected ($n=75$, 27%); SARS-CoV-2-infected *without* respiratory symptoms ($n=88$, 32%); and SARS-CoV-2-infected *with* respiratory symptoms ($n=111$, 41%). Among SARS-CoV-2-infected individuals, nasopharyngeal samples were collected a median (IQR) of 5 (2, 8) days from symptom onset (or SARS-CoV-2 diagnosis in asymptomatic cases). SARS-CoV-2-

infected participants *with* respiratory symptoms were older than SARS-CoV-2-infected participants without respiratory symptoms and SARS-CoV-2-uninfected participants, consistent with our previous observation of a high prevalence of respiratory symptoms among SARS-CoV-2-infected adolescents in this cohort [7]. Similarly, a higher proportion of SARS-CoV-2-infected individuals identified as Latino or Hispanic-American compared to SARS-CoV-2-uninfected individuals [7]. There were no significant differences in the prevalences of comorbidities or recent receipt of antibiotics or probiotics in these groups.

Age-associated changes in nasopharyngeal microbiome composition

Median (IQR) Shannon diversity and Chao1 indices of the nasopharyngeal microbiome were 1.49 (1.12, 2.00) and 70.0 (48.8, 97.2), respectively. Nasopharyngeal microbiome diversity, as measured by the Shannon diversity index, increased with age (**Figure 1a**; $p < 0.0001$), while nasopharyngeal microbiome richness, as measured by the Chao1 index, declined with increasing age (**Figure 1b**; $p = 0.02$). The composition of the nasopharyngeal microbiome also differed according to age (**Figure 1c**; PERMANOVA on Bray-Curtis dissimilarity, $p < 0.001$, $R^2 = 0.103$). In particular, older age was associated with lower abundances of several ASVs classified as *Dolosigranulum*, *Moraxella*, and *Streptococcus*, and higher abundances of specific ASVs classified as *Anaerococcus*, *Corynebacterium*, *Lawsonella*, *Peptoniphilus*, and *Staphylococcus* (**Figure 2** and **Supplemental Table 2**). Infants and young children 5 years of age or younger tended to have high abundances of *Dolosigranulum* and *Moraxella* within their nasopharyngeal microbiomes, while the nasopharyngeal microbiomes of adolescents and young adults 12 years of age or older were frequently dominated by *Staphylococcus*. Additionally, several bacterial genera (*Anaerococcus*, *Lawsonella*, and *Peptoniphilus*) that were of low prevalence and abundance in the nasopharyngeal microbiomes of infants and young children were highly abundant in adolescents and young adults (**Supplemental Table 3**). *Corynebacterium* was highly abundant in the nasopharyngeal microbiome across all age categories and its relative abundance was positively correlated with age.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

Associations between the nasopharyngeal microbiome and SARS-CoV-2 susceptibility

Nasopharyngeal microbiome diversity, as measured by the Shannon diversity index, did not differ in SARS-CoV-2-infected and SARS-CoV-2-uninfected participants (**Figure 1a**; $p=0.36$). In contrast, SARS-CoV-2-infected individuals had higher microbiome richness, measured by the log-transformed Chao1 index, than uninfected individuals (**Figure 1b**; $p=0.008$). Additionally, nasopharyngeal microbiome composition differed in SARS-CoV-2-infected and uninfected participants (**Figure 1c**; PERMANOVA on Bray-Curtis dissimilarity, $p=0.007$, $R^2=0.009$). In ANCOM-II analyses adjusting for age, we identified two ASVs assigned to the bacterial genus *Corynebacterium* that were differentially abundant by SARS-CoV-2 infection status (**Figure 3a** and **Supplemental Table 4**), both of which were of higher abundance in SARS-CoV-2-infected participants relative to uninfected participants. Using BLAST searches, we operationally classified these ASVs as *Corynebacterium accolens/macginleyi/tuberculostrictum*. Notably, the relative abundances of both of these ASVs increased with increasing age independent of SARS-CoV-2 infection status (**Figure 3b** and **Supplemental Table 2**).

Associations between the nasopharyngeal microbiome and SARS-CoV-2-associated respiratory symptoms

SARS-CoV-2 infection results in a broad range of clinical manifestations from completely asymptomatic to severe pneumonia and acute respiratory distress syndrome [33-35]. In particular, we previously reported marked differences in the prevalences of respiratory symptoms among children, adolescents, and young adults with SARS-CoV-2 infection [7]. To evaluate the extent to which the upper respiratory microbiome contributes to the varied clinical presentations of SARS-CoV-2 infection by age, we compared the nasopharyngeal microbiomes of SARS-CoV-2-infected participants *with* respiratory symptoms to those of SARS-CoV-2-infected participants *without* respiratory symptoms. Nasopharyngeal microbiome alpha diversity (Shannon diversity, Chao1 richness) was similar in SARS-CoV-2-infected individuals with or without respiratory symptoms (**Figure 1a** and **Figure 1b**), while nasopharyngeal

microbiome composition differed between these groups (**Figure 1c**; PERMANOVA on Bray-Curtis dissimilarity, $p=0.008$, $R^2=0.014$). In ANCOM-II analyses adjusting for age, we identified nine ASVs that were differentially abundant in SARS-CoV-2-infected participants with or without respiratory symptoms (**Figure 4a** and **Supplemental Table 5**). The two ASVs classified as *Corynebacterium* that were associated with SARS-CoV-2 infection status (ASV 1017, ASV 1030) were also more abundant in SARS-CoV-2-infected individuals *with* respiratory symptoms compared to SARS-CoV-2-infected individuals *without* respiratory symptoms. Additionally, two other *Corynebacterium* ASVs that were identified as *Corynebacterium accolens/macginleyi/tuberculostrictum* (ASV 1014, ASV 1032) were more abundant in SARS-CoV-2-infected participants *with* respiratory symptoms. Other ASVs that were more abundant in SARS-CoV-2-infected participants *with* respiratory symptoms were classified as *Lawsonella clevelandensis* (ASV 1060), *Finegoldia magna* (ASV 1535), *Anaerococcus* spp. (ASV 1593) and *Peptoniphilus* spp. (ASV 1618). Each of the ASVs that were associated with the presence of respiratory symptoms in SARS-CoV-2-infected individuals were independently and positively associated with increasing age (**Figure 4b** and **Supplemental Table 2**), with several ASVs that were almost exclusively detected in adolescents 12 years of age or older. We also identified a single ASV that was assigned to *Dolosigranulum pigrum* (ASV 1491) that was of lower abundance in SARS-CoV-2-infected participants with respiratory symptoms and additionally declined in abundance with increasing age. Finally, nasopharyngeal microbiome composition also differed between SARS-CoV-2-infected participants *with* respiratory symptoms and SARS-CoV-2-uninfected participants (PERMANOVA on Bray-Curtis dissimilarity, $p<0.001$, $R^2=0.015$), with several of these same *Corynebacterium* ASVs (ASV 1017, ASV 1030, ASV 1032) and ASVs classified as *Anaerococcus* spp. (ASV 1582) and *Peptoniphilus* spp. (ASV 1618) being more abundant in the nasopharyngeal microbiomes of SARS-CoV-2-infected participants *with* respiratory symptoms (**Supplemental Table 6**).

DISCUSSION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

In this study, we found that higher abundances of specific *Corynebacterium* ASVs are associated with SARS-CoV-2 infection among children, adolescents, and young adults with a SARS-CoV-2-infected close contact. In addition, we identified nasopharyngeal microbiome alterations, including higher abundances of *Corynebacterium* and lower abundances of *D. pigrum*, that are associated with the presence of respiratory symptoms in the setting of confirmed SARS-CoV-2 infection. Finally, we demonstrate that these same microbiome features are strongly, and independently, associated with increasing age. Our findings suggest that the upper respiratory microbiome may be a previously unrecognized and potentially modifiable mechanism by which age influences SARS-CoV-2 susceptibility and illness severity.

Over the past several decades, accumulating data have emerged demonstrating that the upper respiratory microbiome plays a key role in the pathogenesis of respiratory virus infections. First, several studies indicate that the upper respiratory microbiome modifies susceptibility to respiratory virus infections, as has been most clearly demonstrated for influenza viruses through household transmission studies [15, 16]. Among 436 household contacts in one of these studies, higher abundances of *Streptococcus* spp. and *Prevotella salivae* within the nasal/oropharyngeal microbiome were associated with lower susceptibility to influenza A infection [15]. Additionally, the upper respiratory microbiome may also influence the symptoms experienced by individuals when respiratory virus infection does occur, presumably through modulation of the host immune response [36]. For instance, the nasopharyngeal microbiome appears to modify the severity of respiratory syncytial virus (RSV) infection among young children, with several studies reporting that higher abundances of *Haemophilus* species are associated with a more exuberant host immune response to RSV [17-19]. Nasopharyngeal microbiome profiles are also associated with the levels of inflammatory cytokines in nasal wash samples and the development of symptomatic infection in adults following experimental rhinovirus challenge [20, 21]. Additionally, intranasal administration of

live bacterial strains has been shown to directly modulate immune responses to influenza viruses and RSV in animal models [37-40]. While data from clinical studies are currently lacking, this work illustrates the potential that targeted manipulation of the upper respiratory microbiome holds for the prevention and treatment of respiratory virus infections.

To date, studies of the upper respiratory microbiome and SARS-CoV-2 infection have been conducted among small cohorts of adults presenting with clinical suspicion of COVID-19. De Maio and colleagues did not find any differences in the nasopharyngeal microbiomes of 18 individuals with symptomatic SARS-CoV-2 infection and 22 individuals with acute respiratory symptoms who tested negative for SARS-CoV-2 [41]. Conversely, a study of 59 adults identified several ASVs that were differentially abundant in those with SARS-CoV-2 infection and in those with higher viral loads during COVID-19, including higher abundances of ASVs classified as *Peptoniphilus lacrimalis*, *Prevotella copri*, and *Anaerococcus* spp. [42]. By comparison, Mostafa and colleagues reported lower nasopharyngeal microbial diversity, a lower abundance of the bacterial family Propionibacteriaceae, and a higher abundance of *Corynebacterium accolens* in 40 SARS-CoV-2-infected adults compared to 10 SARS-CoV-2-uninfected adults with suspected COVID-19 [43]. Consistent with findings from this latter study, and in the largest cohort studied to date, here we demonstrated that ASVs assigned to *Corynebacterium* spp. (*C. accolens/macginleyi/tuberculostrictum*) were associated with SARS-CoV-2 infection among 274 children, adolescents, and adults with SARS-CoV-2 exposure. In addition, we identified novel associations between ASVs assigned to *Corynebacterium* spp., *Lawsonella clevelandensis*, *Finegoldia magna*, *Anaerococcus* spp., *Peptoniphilus* spp., and *Dolosigranulum pigrum* and the presence of respiratory symptoms during SARS-CoV-2 infection. Notably, the changes in relative abundances of these ASVs that were associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory symptoms were also independently associated with increasing age, suggesting that age-associated changes

in the upper respiratory microbiome may underlie the differences in SARS-CoV-2 susceptibility and illness severity that exist between children and adults.

Non-diphtheriae *Corynebacterium* species and *D. pigrum* were previously shown to have important microbial interactions within the human nasopharynx. In particular, the abundance of *Corynebacterium* within the nasopharyngeal microbiome has been negatively associated with colonization by *Streptococcus pneumoniae* among infants and children [44-47], while the relative abundance of *D. pigrum* within the nasopharyngeal microbiome has been negatively associated with the co-occurrence of both *S. pneumoniae* and *S. aureus* [47, 48]. Few prior clinical studies identified associations between these bacterial species and the risk and severity of respiratory virus infections. Interestingly, strains of *Corynebacterium* spp. and *D. pigrum* have been shown to influence innate immune responses to influenza and RSV in murine models [49-51], suggesting that these bacterial commensals may influence overall immunological tone within the upper respiratory tract. Importantly, much of the work on these bacterial species has been conducted in young children [44-48], and surprisingly little is known about the abundances and functions of these microbes in the upper respiratory tracts of adults. Taken together, these studies suggest that specific strains of commensal bacteria have differential impacts on host immune responses to potential pathogens and that age-associated changes in the relative abundance of different species likely plays a critical role in infection susceptibility.

Previous studies demonstrated that the nasopharyngeal microbiome is a relatively low-diversity ecological niche in young children and older adults. Importantly, relatively few bacterial genera comprise the majority of the nasopharyngeal microbiome during infancy and early childhood, with microbiome composition being influenced by breastfeeding [14, 52], mode of delivery [53, 54], acute respiratory infections [12], antibiotic treatment [12], and season [55]. Studies of older children and adolescents have primarily focused on the nasopharyngeal microbiome of individuals with asthma and other chronic

respiratory diseases [56-59]. Pérez-Losada and colleagues profiled the nasopharyngeal microbiomes of 40 children and adolescents 6-17 years of age with asthma, and found that the most abundant genera were *Moraxella*, *Staphylococcus*, *Dolosigranulum*, *Corynebacterium*, *Prevotella*, and *Streptococcus* [60]. Several of these bacterial genera are reported to be highly abundant in the nasopharyngeal microbiomes of healthy adults and adults with asthma [61, 62]. To our knowledge, there are no prior studies that evaluated upper respiratory microbiome profiles from infancy through early adulthood. Our findings demonstrate that the nasopharyngeal microbiome continues to develop throughout childhood and adolescence. Future studies should investigate the biological or environmental factors that contribute to the shifts in microbiome composition that occur after early childhood.

Our study had several limitations. First, nasopharyngeal samples were collected at a single time point, and we did not have nasopharyngeal samples prior to infection in SARS-CoV-2-infected participants. Therefore, we were unable to determine if the differences in nasopharyngeal microbiome composition observed by SARS-CoV-2 infection status preceded, or were the consequence of, SARS-CoV-2 infection. Secondly, all of the SARS-CoV-2-infected study participants had relatively mild symptoms, and no study participants required antiviral treatment or hospitalization. We therefore were unable to evaluate if the microbiome features that we identified as being associated with SARS-CoV-2 respiratory symptoms are additionally associated with severe COVID-19. In addition, our use of 16S rRNA gene amplicon sequencing prevented us from evaluating other components of the upper respiratory microbiome, including viruses and fungi. Additionally, 16S rRNA gene amplicon experiments have several well-documented biases [63], although we sought to minimize these biases in our study through inclusion of all samples in a single processing run and use of appropriate negative controls. Finally, although analyses adjusted for age in evaluating associations between the nasopharyngeal microbiome and SARS-CoV-2 susceptibility and illness severity, residual confounding by unmeasured factors remains possible.

1 In conclusion, we found that age-associated changes in the nasopharyngeal microbiome are independently
2 associated with SARS-CoV-2 infection and SARS-CoV-2-associated respiratory symptoms among
3 children, adolescents, and young adults. These findings suggest that development of the nasopharyngeal
4 microbiome during childhood and adolescence may contribute to the differences in SARS-CoV-2
5 susceptibility and severity observed by age. Future studies should evaluate the potential of the upper
6 respiratory microbiome to serve as a therapeutic target for the prevention and treatment of infections
7 caused by SARS-CoV-2 and other respiratory viruses.

1 **ACKNOWLEDGEMENTS**

2

3 We would like to thank the Duke University School of Medicine for use of the Microbiome Core Facility,
 4 which performed the DNA extractions and library preparations for this research, and the Duke
 5 Sequencing and Genomic Technologies Core Facility, which sequenced these libraries. We offer our
 6 sincere gratitude to the children and families who participated in this research.

7

8 **DECLARATIONS**

9

10 **Ethics approval and consent to participate**

11 This study was approved by the Duke University Health System Institutional Review Board. Written
 12 informed consent was obtained from all participants or their legal guardian.

13

14 **Availability of data and materials**

15 The sequencing dataset supporting the conclusions of this study is available in the Sequence Read
 16 Archive (PRJNA703574). The statistical files and script used for data analyses are also publicly available
 17 (https://github.com/alexmccumber/BRAVE_Kids).

18

19 **Competing Interests**

20 MSK reports advisory board fees from Adagio Therapeutics, Inc. CWW reports advisory board fees
 21 from Roche Molecular Sciences, non-financial support from bioMérieux and Becton Dickinson, a
 22 research collaboration with Biofire, and is co-founder of Predigen. All other authors have no competing
 23 interests to declare.

24

25

1 **Funding**

2 This work was funded by the Duke University School of Medicine and through grants from the Duke
3 Microbiome Center, Children’s Miracle Network Hospitals, and the Translating Duke Health Children’s
4 Health and Discovery Initiative. AWM was supported by a grant from the National Science Foundation
5 (DGE-1545220). SMH was supported by National Institutes of Health (NIH) training grant (T32-
6 HD094671). MSK was supported by a NIH Career Development Award (K23-AI135090).

7

8 **Author contributions**

9 JHH, AWM, SMH, MAM, JFR, CWW, and MSK contributed to the study concept and design. JNA, JR,
10 DJL, ATR, NAT, TSP, TCG, and TND collected the data or assisted with data analysis or interpretation.
11 JHH, AWM, and MSK drafted the manuscript and all other authors revised it critically for important
12 intellectual content. All authors approved of the final version of the manuscript.

REFERENCES

1. Dong E, Du H, Gardner L. *An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis; published online Feb 19. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).*
2. Welliver, R.C., *Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. The Journal of pediatrics, 2003. 143(5): p. 112-117.*
3. Laurichesse, H., et al., *Epidemiological features of parainfluenza virus infections: laboratory surveillance in England and Wales, 1975–1997. European journal of epidemiology, 1999. 15(5): p. 475-484.*
4. Piotrowska, Z., et al., *Rhinoviruses are a major cause of wheezing and hospitalization in children less than 2 years of age. The Pediatric infectious disease journal, 2009. 28(1): p. 25.*
5. Viner, R.M., et al., *Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. JAMA Pediatrics, 2021. 175(2): p. 143-156.*
6. *COVID-19 Stats: COVID-19 Incidence, by Age Group — United States, March 1–November 14, 2020. MMWR Morb Mortal Wkly Rep 2021;69:1664. doi: <http://dx.doi.org/10.15585/mmwr.mm695152a8>.*
7. Hurst, J.H., et al., *SARS-CoV-2 Infections Among Children in the Biospecimens from Respiratory Virus-Exposed Kids (BRAVE Kids) Study. Clin Infect Dis, 2020.*
8. Castagnoli, R., et al., *Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatrics, 2020. 174(9): p. 882-889.*
9. Yousaf, A.R., et al., *A prospective cohort study in non-hospitalized household contacts with SARS-CoV-2 infection: symptom profiles and symptom change over time. Clin Infect Dis, 2020.*
10. Han, M.S., et al., *Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatr, 2021. 175(1): p. 73-80.*

11. Kim, L., et al., *Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020*. MMWR Morb Mortal Wkly Rep, 2020. **69**(32): p. 1081-1088.
12. Teo, S.M., et al., *The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development*. Cell host & microbe, 2015. **17**(5): p. 704-715.
13. Mika, M., et al., *Dynamics of the nasal microbiota in infancy: A prospective cohort study*. Journal of Allergy and Clinical Immunology, 2015. **135**(4): p. 905-912. e11.
14. Biesbroek, G., et al., *Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children*. American journal of respiratory and critical care medicine, 2014. **190**(11): p. 1283-1292.
15. Tsang, T.K., et al., *Association between the respiratory microbiome and susceptibility to influenza virus infection*. Clinical Infectious Diseases, 2020. **71**(5): p. 1195-1203.
16. Lee, K.H., et al., *The respiratory microbiome and susceptibility to influenza virus infection*. PLOS ONE, 2019. **14**(1): p. e0207898.
17. Chu, C.-Y., et al., *Airway Gene Expression Correlates of Respiratory Syncytial Virus Disease Severity and Microbiome Composition in Infants*. The Journal of Infectious Diseases, 2020.
18. Ederveen, T.H., et al., *Haemophilus is overrepresented in the nasopharynx of infants hospitalized with RSV infection and associated with increased viral load and enhanced mucosal CXCL8 responses*. Microbiome, 2018. **6**(1): p. 1-13.
19. de Steenhuijsen Piters, W.A., et al., *Nasopharyngeal Microbiota, Host Transcriptome and Disease Severity in Children with Respiratory Syncytial Virus Infection*. American journal of respiratory and critical care medicine, 2016(ja).
20. Lehtinen, M.J., et al., *Nasal microbiota clusters associate with inflammatory response, viral load, and symptom severity in experimental rhinovirus challenge*. Scientific Reports, 2018. **8**(1): p. 11411.

21. Allen, E.K., et al., *Characterization of the nasopharyngeal microbiota in health and during rhinovirus challenge*. Microbiome, 2014. **2**(1): p. 22.
22. Gilbert, J.A., et al., *Meeting report: the terabase metagenomics workshop and the vision of an Earth microbiome project*. Stand Genomic Sci, 2010. **3**(3): p. 243-8.
23. Callahan, B.J., et al., *DADA2: high-resolution sample inference from Illumina amplicon data*. Nature methods, 2016. **13**(7): p. 581.
24. McLaren MR. *Silva SSU taxonomic training data formatted for DADA2 (Silva version 138)*, 2020. Available at: <http://doi.org/10.5281/zenodo.3986799>.
25. Davis, N.M., et al., *Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data*. Microbiome, 2018. **6**(1): p. 226.
26. Camacho, C., et al., *BLAST+: architecture and applications*. BMC Bioinformatics, 2009. **10**: p. 421.
27. McMurdie, P.J. and S. Holmes, *phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data*. PloS one, 2013. **8**(4): p. e61217.
28. Oksanen, J., et al., *The vegan package*. Community ecology package, 2007. **10**(631-637): p. 719.
29. Kaul, A., et al., *Analysis of microbiome data in the presence of excess zeros*. Frontiers in microbiology, 2017. **8**: p. 2114.
30. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2*. Genome Biology, 2014. **15**(12): p. 550.
31. R Core Team (2019). *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>.
32. H. Wickham. *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York, 2016.
33. He, X., et al., *Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis*. Front Public Health, 2020. **8**: p. 561264.

- 1 34. Zhu, J., et al., *Clinical characteristics of 3062 COVID-19 patients: A meta-analysis*. J Med Virol,
2 2020. **92**(10): p. 1902-1914.
- 3 35. Tenforde, M.W., et al., *Characteristics of adult outpatients and inpatients with COVID-19—11*
4 *academic medical centers, United States, March–May 2020*. Morbidity and Mortality Weekly
5 Report, 2020. **69**(26): p. 841.
- 6 36. Pichon, M., B. Lina, and L. Josset, *Impact of the respiratory microbiome on host responses to*
7 *respiratory viral infection*. Vaccines, 2017. **5**(4): p. 40.
- 8 37. Tomosada, Y., et al., *Nasally administered Lactobacillus rhamnosus strains differentially*
9 *modulate respiratory antiviral immune responses and induce protection against respiratory*
10 *syncytial virus infection*. BMC immunology, 2013. **14**(1): p. 40.
- 11 38. Zelaya, H., et al., *Nasal priming with immunobiotic Lactobacillus rhamnosus modulates*
12 *inflammation–coagulation interactions and reduces influenza virus-associated pulmonary*
13 *damage*. Inflammation Research, 2015. **64**(8): p. 589-602.
- 14 39. Hori, T., et al., *Effect of intranasal administration of Lactobacillus casei Shirota on influenza*
15 *virus infection of upper respiratory tract in mice*. Clin Diagn Lab Immunol, 2001. **8**(3): p. 593-7.
- 16 40. Harata, G., et al., *Intranasal administration of Lactobacillus rhamnosus GG protects mice from*
17 *H1N1 influenza virus infection by regulating respiratory immune responses*. Letters in applied
18 microbiology, 2010. **50**(6): p. 597-602.
- 19 41. De Maio, F., et al., *Nasopharyngeal microbiota profiling of SARS-CoV-2 infected patients*.
20 Biological procedures online, 2020. **22**(1): p. 1-4.
- 21 42. Rosas-Salazar, C., et al., *SARS-CoV-2 Infection and Viral Load are Associated with the Upper*
22 *Respiratory Tract Microbiome*. Journal of Allergy and Clinical Immunology, 2021.
- 23 43. Mostafa, H.H., et al., *Metagenomic next-generation sequencing of nasopharyngeal specimens*
24 *collected from confirmed and suspect covid-19 patients*. Mbio, 2020. **11**(6).

44. Kelly, M.S., et al., *The nasopharyngeal microbiota of children with respiratory infections in Botswana*. The Pediatric infectious disease journal, 2017. **36**(9): p. e211.
45. Bomar, L., et al., *Corynebacterium accolens releases antipneumococcal free fatty acids from human nostril and skin surface triacylglycerols*. MBio, 2016. **7**(1): p. e01725-15.
46. Khamash, D.F., et al., *The Association Between the Developing Nasal Microbiota of Hospitalized Neonates and Staphylococcus aureus Colonization*. Open Forum Infectious Diseases, 2019. **6**(4).
47. Laufer, A.S., et al., *Microbial communities of the upper respiratory tract and otitis media in children*. MBio, 2011. **2**(1): p. e00245-10.
48. Brugger, S.D., et al., *Dolosigranulum pigrum cooperation and competition in human nasal microbiota*. Msphere, 2020. **5**(5).
49. Ortiz Moyano, R., et al., *The ability of respiratory commensal bacteria to beneficially modulate the lung innate immune response is a strain dependent characteristic*. Microorganisms, 2020. **8**(5): p. 727.
50. Kanmani, P., et al., *Respiratory commensal bacteria Corynebacterium pseudodiphtheriticum improves resistance of infant mice to respiratory syncytial virus and Streptococcus pneumoniae superinfection*. Frontiers in microbiology, 2017. **8**: p. 1613.
51. Mak, N., E. Schiltknecht, and G. Ada, *Protection of mice against influenza virus infection: enhancement of nonspecific cellular responses by Corynebacterium parvum*. Cellular immunology, 1983. **78**(2): p. 314-325.
52. Biesbroek, G., et al., *The impact of breastfeeding on nasopharyngeal microbial communities in infants*. American journal of respiratory and critical care medicine, 2014. **190**(3): p. 298-308.
53. Bosch, A.A., et al., *Development of upper respiratory tract microbiota in infancy is affected by mode of delivery*. EBioMedicine, 2016. **9**: p. 336-345.

- 1 54. Dominguez-Bello, M.G., et al., *Delivery mode shapes the acquisition and structure of the initial*
2 *microbiota across multiple body habitats in newborns*. Proceedings of the National Academy of
3 Sciences, 2010. **107**(26): p. 11971-11975.
- 4 55. Bogaert, D., et al., *Variability and diversity of nasopharyngeal microbiota in children: a*
5 *metagenomic analysis*. Plos one, 2011. **6**(2): p. e17035.
- 6 56. Hilty, M., et al., *Disordered microbial communities in asthmatic airways*. PloS one, 2010. **5**(1): p.
7 e8578.
- 8 57. Marri, P.R., et al., *Asthma-associated differences in microbial composition of induced sputum*.
9 Journal of Allergy and Clinical Immunology, 2013. **131**(2): p. 346-352. e3.
- 10 58. Zhang, Q., et al., *Airway microbiota in severe asthma and relationship to asthma severity and*
11 *phenotypes*. PLoS one, 2016. **11**(4): p. e0152724.
- 12 59. Hahn, A., et al., *Microbial diversity within the airway microbiome in chronic pediatric lung*
13 *diseases*. Infection, Genetics and Evolution, 2018. **63**: p. 316-325.
- 14 60. Pérez-Losada, M., et al., *Nasopharyngeal Microbiome Diversity Changes over Time in Children*
15 *with Asthma*. PLoS One, 2017. **12**(1): p. e0170543.
- 16 61. Stearns, J.C., et al., *Culture and molecular-based profiles show shifts in bacterial communities of*
17 *the upper respiratory tract that occur with age*. Isme j, 2015. **9**(5): p. 1246-59.
- 18 62. Bomar, L., S.D. Brugger, and K.P. Lemon, *Bacterial microbiota of the nasal passages across the*
19 *span of human life*. Current opinion in microbiology, 2018. **41**: p. 8-14.
- 20 63. Brooks, J.P., et al., *The truth about metagenomics: quantifying and counteracting bias in 16S*
21 *rRNA studies*. BMC Microbiology, 2015. **15**(1): p. 66.
- 22

1 FIGURES

2

3 **Figure 1. Nasopharyngeal microbiome alpha and beta diversity by age and SARS-CoV-2 clinical**
4 **status.** Shannon diversity (a) and Chao1 richness (b) is shown for each age group by clinical status:
5 SARS-CoV-2-uninfected (green), SARS-CoV-2-infected *without* respiratory symptoms (purple), and
6 SARS-CoV-2-infected *with* respiratory symptoms (orange). Points represent individual samples while the
7 line denotes means for samples from each group in each age category. (c) Non-metric multidimensional
8 scaling plot based on Bray-Curtis distances is shown by age category and according to SARS-CoV-2

1 clinical status [(SARS-CoV-2-uninfected (green), SARS-CoV-2-infected *without* respiratory symptoms
2 (purple), and SARS-CoV-2-infected *with* respiratory symptoms (orange)]. Within each panel
3 corresponding to an age category, the colored points represent samples for the corresponding age
4 category, while the gray points represent samples collected from children in other age categories.

5

1

2

3

4

5

Figure 2. Relative abundances of highly abundant genera by age. Each bar depicts the mean relative abundances of highly abundant genera in nasopharyngeal samples from participants in a specific age category. Only the nine most highly abundant genera within nasopharyngeal samples from the entire study population are shown.

Figure 3. Relative abundances of ASVs that were differentially abundant by SARS-CoV-2 infection status. a) Boxplots of the relative abundances of ASVs that were differentially abundant by SARS-CoV-2 infection status in age-adjusted analyses conducted in ANCOM-II. a) Boxplots of the relative abundances by age group of ASVs that were differentially abundant by SARS-CoV-2 infection status in age-adjusted analyses conducted in ANCOM-II. Relative abundances are plotted on a log scale with 1E-6 added to all counts to enable transformation of zero counts. Rectangles represent the lower quartile, median, and upper quartile of the relative abundances of each ASV. The relative abundances of two ASVs classified as *Corynebacterium accolens/macginleyi/tuberculostearicum* were higher in SARS-CoV-2-infected individuals compared to uninfected individuals, adjusting for age (ASV 1017, $W=192$; ASV 1030, $W=233$). In addition, the relative abundances of these *Corynebacterium* ASVs increased with increasing age adjusting for SARS-CoV-2 infection status and the presence of SARS-CoV-2-associated respiratory symptoms (ASV 1017, $W=170$; ASV 1030, $W=173$).

Figure 4. Relative abundances of ASVs that were differentially abundant by SARS-CoV-2-associated respiratory symptoms. a) Boxplots of the relative abundances of ASVs that were differentially abundant by the presence of respiratory symptoms in SARS-CoV-2-infected individuals in age-adjusted analyses performed in ANCOM-II. b) Boxplots of the relative abundances by age group of ASVs that were differentially abundant by SARS-CoV-2 infection status in age-adjusted analyses

1 conducted in ANCOM-II. Relative abundances are plotted on a log scale with 1E-6 added to all counts to
2 enable transformation of zero counts. Rectangles represent the lower quartile, median, and upper quartile
3 of the relative abundances of each ASV. Adjusting for age, SARS-CoV-2-associated respiratory
4 symptoms were associated with higher abundances of ASVs assigned to *Corynebacterium* spp. (ASV
5 1014, W=268; ASV 1017, W=233; ASV 1030, W=271; ASV 1032, W=229), *Lawsonella clevelandensis*
6 (ASV 1060, W=273), *Finegoldia magna* (ASV 1535, W=265), *Anaerococcus* spp. (ASV 1593, W=231),
7 and *Peptoniphilus* spp. (ASV 1618, W=271). The relative abundances of each of these ASVs additionally
8 increased with increasing age adjusting for SARS-CoV-2 infection status and the presence of SARS-CoV-
9 2-associated respiratory symptoms (ASV 1014, W=173; ASV 1017, W=170; ASV 1030, W=173; ASV
10 1032, W=170; ASV 1060, W=173; ASV 1535, W=172; ASV 1593, W=169; ASV 1618, W=173).
11 Adjusting for age, SARS-CoV-2-associated respiratory symptoms were associated with a lower
12 abundance of a single ASV assigned to *Dolosigranulum pigrum* (ASV 1491, W=260), and the relative
13 abundance of this ASV decreased with increasing age adjusting for SARS-CoV-2 infection status and the
14 presence of SARS-CoV-2-associated respiratory symptoms (ASV 1491, W=171).

1 SUPPLEMENTAL MATERIALS

2

3 **Supplemental Table 1.** Taxonomic classification and reference sequences for ASVs identified in
4 nasopharyngeal samples from the study population

5

6 **Supplemental Table 2.** Differentially abundant ASVs by age in ANCOM-II analyses adjusting for
7 SARS-CoV-2-infection status and SARS-CoV-2-associated respiratory symptoms

8

9 **Supplemental Table 3.** Prevalences and relative abundances of highly abundant bacterial genera by age

10

11 **Supplemental Table 4.** Differentially abundant ASVs by SARS-CoV-2 infection status in ANCOM-II
12 analyses adjusting for age

13

14 **Supplemental Table 5.** Differentially abundant ASVs among SARS-CoV-2-infected individuals by the
15 presence of respiratory symptoms in ANCOM-II analyses adjusting for age

16

17 **Supplemental Table 6.** Differentially abundant ASVs in analyses comparing SARS-CoV-2-infected
18 individuals *with* respiratory symptoms to SARS-CoV-2-uninfected individuals in ANCOM-II analyses
19 adjusting for age

Table 1. Characteristics of the study population

	SARS-CoV-2-Exposed, Uninfected (n=75)		SARS-CoV-2-Infected Without Respiratory Symptoms (n=88)		SARS-CoV-2-Infected With Respiratory Symptoms (n=111)		<i>P</i>
	N (or median)	% (or IQR)	N (or median)	% (or IQR)	N (or median)	% (or IQR)	
Age, years	9.2	(5.0–16.7)	9.1	(5.1–14.2)	14.2	(6.5–17.5)	0.006
Female sex	38	51%	49	56%	57	49%	0.77
Race							<0.0001
Black or African-American	3	4%	5	6%	8	7%	
Latino or Hispanic-American	43	57%	77	88%	99	89%	
Non-Hispanic white	29	39%	6	7%	4	4%	
Comorbidities							
Provider-diagnosed asthma	8	11%	6	7%	9	8%	0.67
Obesity (BMI ≥95 th percentile for age)	21	28%	21	24%	40	36%	0.16
Receipt of antibiotic in prior 30 days	1	1%	2	2%	3	3%	0.88
Receipt of probiotic in prior 30 days	2	3%	0	0%	1	1%	0.37

IQR, interquartile range; BMI, body mass index